Physician profile
David E Gerber
NPI 1336295039
$81,143.38
in general payments reported to CMS, 2019-2025
19 companies · $17K in 2025
The $17K reported for 2025 was more than what 86% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $5,024 · 2021: $26K · 2022: $7,101 · 2023: $17K · 2024: $8,741 · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $30K · Honoraria: $7,525 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,120 · Travel and Lodging: $1,004 · Food and Beverage: $596.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $30,402.75 |
| Honoraria | $7,525.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,120.00 |
| Travel and Lodging | $1,003.89 |
| Food and Beverage | $595.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Catalyst Pharmaceuticals, INC. | $17,449.31 | 2020-2023 | Firdapse |
| Bayer Healthcare Pharmaceuticals INC. | $10,525.02 | 2025 | |
| Genzyme Corporation | $10,210.00 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $6,429.97 | 2023 | Tagrisso |
| Daiichi Sankyo INC. | $6,336.25 | 2024-2025 | Enhertu |
| Regeneron Healthcare Solutions, INC. | $5,864.50 | 2021-2025 | Libtayo |
| Janssen Biotech, INC. | $4,960.00 | 2021-2022 | |
| Janssen Scientific Affairs, LLC | $4,040.00 | 2021 | |
| Glaxosmithkline, LLC. | $3,200.00 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $3,120.00 | 2023 | |
| Genentech USA, INC. | $2,200.00 | 2022 | |
| Abbvie INC. | $2,175.00 | 2024 | |
| Beigene, LTD. | $1,950.00 | 2021 | |
| Regeneron Pharmaceuticals, INC. | $1,788.15 | 2021 | |
| Merck Sharp & Dohme LLC | $776.58 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $118.60 | 2021-2025 | Lumakras |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Gerber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.